Zimmer Yitzhak

Prof. Dr. Zimmer Yitzhak

Department of Radiation Oncology, Universitat Bern, Bern, Switzerland

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2023 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
LHLusine Hovhannisyan
Lusine Hovhannisyan
CRCarsten Riether
Carsten Riether
DADaniel M. Aebersold
Daniel M. Aebersold
MMMichaela Medová
Michaela Medová
ZYZimmer Yitzhak
Zimmer Yitzhak
CAR T cell-based therapies have revolutionized the treatment of hematological malignancies such as leukemia and lymphoma within the last years. In contrast to the success in hematological cancers, the treatment of solid tumors with CAR T cells is still a major challenge in the field and attempts to overcome these hurdles have not been successful yet. Radiation therapy is used for management of various malignancies for decades and its therapeutic role ranges from local therapy to a priming agent in cancer immunotherapy. Combinations of radiation with immune checkpoint inhibitors have already proven successful in clinical trials. Therefore, a combination of radiation therapy may have the potential to overcome the current limitations of CAR T cell therapy in solid tumor entities. So far, only limited research was conducted in the area of CAR T cells and radiation. In this review we will discuss the potential and risks of such a combination in the treatment of cancer patients.

11 March 2011 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
MMMichaela Medova
Michaela Medova
DADaniel M Aebersold
Daniel M Aebersold
ZYZimmer Yitzhak
Zimmer Yitzhak
Abnormal activation of cellular DNA repair pathways by deregulated signaling of receptor tyrosine kinase systems has broad implications for both cancer biology and treatment. Recent studies suggest a potential link between DNA repair and aberrant activation of the hepatocyte growth factor receptor Mesenchymal‐Epithelial Transition (MET), an oncogene that is overexpressed in numerous types of human tumors and considered a prime target in clinical oncology. Using the homologous recombination (HR) direct‐repeat direct‐repeat green fluorescent protein ((DR)‐GFP) system, we show that MET inhibition in tumor cells with deregulated MET activity by the small molecule PHA665752 significantly impairs in a dose‐dependent manner HR. Using cells that express MET‐mutated variants that respond differentially to PHA665752, we confirm that the observed HR inhibition is indeed MET‐dependent. Furthermore, our data also suggest that decline in HR‐dependent DNA repair activity is not a secondary effect due to cell cycle alterations caused by PHA665752. Mechanistically, we show that MET inhibition affects the formation of the RAD51‐BRCA2 complex, which is crucial for error‐free HR repair of double strand DNA lesions, presumably via downregulation and impaired translocation of RAD51 into the nucleus. Taken together, these findings assist to further support the role of MET in the cellular DNA damage response and highlight the potential future benefit of MET inhibitors for the sensitization of tumor cells to DNA damaging agents.

1 October 2010 in Genes & Cancer
Verified
Journal Article
Closed access
MMMichaela Medova
Michaela Medova
DAD. M. Aebersold
D. M. Aebersold
WBW. Blank-Liss
W. Blank-Liss
BSB. Streit
B. Streit
MMMatúš Medo
Matúš Medo
ZYZimmer Yitzhak
Zimmer Yitzhak
While recent studies implicate that signaling through the receptor tyrosine kinase MET protects cancer cells from DNA damage, molecular events linking MET to the DNA damage response machinery are largely unknown. Here, we studied the impact of MET inhibition by the small molecule PHA665752 on cytotoxicity induced by DNA-damaging agents. We demonstrate that PHA665752 reduces clonogenic survival of tumor cells with MET overexpression when combined with ionizing radiation and synergistically cooperates with ionizing radiation or adriamycin to induce apoptosis. In search of mechanisms underlying the observed synergism, we show that PHA665752 alone considerably increases γH2AX levels, indicating the accumulation of double-strand DNA breaks. In addition, PHA665752 treatment results in sustained high levels of γH2AX and phosphorylated ATM postirradiation, strengthening the assumption that MET inhibition attenuates postdamage DNA repair. PHA665752, alone or in combination with irradiation, leads also to a massive increase of γH2AX tyrosine phosphorylation and its subsequent interaction with the proapoptotic kinase JNK1. Finally, MET inhibition reduces activation of ATR, CHK1, and CDC25B and abrogates an associated DNA damage-induced S phase arrest. This indicates that MET inhibition compromises a critical damage-dependent checkpoint that may enable DNA-damaged cells to exit cell cycle arrest before repair is completed.

1 November 2020 in Pharmacology & Therapeutics
Verified
Journal Article
Open access
MMMichaela Medová
Michaela Medová
MMMatúš Medo
Matúš Medo
LHLusine Hovhannisyan
Lusine Hovhannisyan
CMCarmen Muñoz-Maldonado
Carmen Muñoz-Maldonado
DADaniel M. Aebersold
Daniel M. Aebersold
ZYZimmer Yitzhak
Zimmer Yitzhak
The DNA-PK holoenzyme is a fundamental element of the DNA damage response machinery (DDR), which is responsible for cellular genomic stability. Consequently, and predictably, over the last decades since its identification and characterization, numerous pre-clinical and clinical studies reported observations correlating aberrant DNA-PK status and activity with cancer onset, progression and responses to therapeutic modalities. Notably, various studies have established in recent years the role of DNA-PK outside the DDR network, corroborating its role as a pleiotropic complex involved in transcriptional programs that operate biologic processes as epithelial to mesenchymal transition (EMT), hypoxia, metabolism, nuclear receptors signaling and inflammatory responses. In particular tumor entities as prostate cancer, immense research efforts assisted mapping and describing the overall signaling networks regulated by DNA-PK that control metastasis and tumor progression. Correspondingly, DNA-PK emerges as an obvious therapeutic target in cancer and data pertaining to various pharmacological approaches have been published, largely in context of combination with DNA-damaging agents (DDAs) that act by inflicting DNA double strand breaks (DSBs). Currently, new generation inhibitors are tested in clinical trials. Several excellent reviews have been published in recent years covering the biology of DNA-PK and its role in cancer. In the current article we are aiming to systematically describe the main findings on DNA-PK signaling in major cancer types, focusing on both preclinical and clinical reports and present a detailed current status of the DNA-PK inhibitors repertoire.

29 July 2009 in Clinical & Experimental Metastasis
Verified
Journal Article
Closed access
PDF file
PGPirus Ghadjar
Pirus Ghadjar
WBWieslawa Blank-Liss
Wieslawa Blank-Liss
MSMathew Simcock
Mathew Simcock
IHIvan Hegyi
Ivan Hegyi
KBKarl T. Beer
Karl T. Beer
ZYZimmer Yitzhak
Zimmer Yitzhak

1 November 2013 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
MMMichaela Medova
Michaela Medova
BPBenoît Pochon
Benoît Pochon
BSBruno Streit
Bruno Streit
WBWieslawa Blank-Liss
Wieslawa Blank-Liss
PFPaola Francica
Paola Francica
ZYZimmer Yitzhak
Zimmer Yitzhak
The receptor tyrosine kinase MET is a prime target in clinical oncology due to its aberrant activation and involvement in the pathogenesis of a broad spectrum of malignancies. Similar to other targeted kinases, primary and secondary mutations seem to represent an important resistance mechanism to MET inhibitors. Here, we report the biologic activity of a novel MET inhibitor, EMD1214063, on cells that ectopically express the mutated MET variants M1268T, Y1248H, H1112Y, L1213V, H1112L, V1110I, V1206L, and V1238I. Our results show a dose-dependent decrease in MET autophosphorylation in response to EMD1214063 in five of the eight cell lines (IC50 2–43 nmol/L). Blockade of MET by EMD1214063 was accompanied by a reduced activation of downstream effectors in cells expressing EMD1214063-sensitive mutants. In all sensitive mutant-expressing lines, EMD1214063 altered cell-cycle distribution, primarily with an increase in G1 phase. EMD1214063 strongly influenced MET-driven biologic functions, such as cellular morphology, MET-dependent cell motility, and anchorage-independent growth. To assess the in vivo efficacy of EMD1214063, we used a xenograft tumor model in immunocompromised mice bearing NIH3T3 cells expressing sensitive and resistant MET-mutated variants. Animals were randomized for the treatment with EMD1214063 (50 mg/kg/d) or vehicle only. Remarkably, five days of EMD1214063 treatment resulted in a complete regression of the sensitive H1112L-derived tumors, whereas tumor growth remained unaffected in mice with L1213V tumors and in vehicle-treated animals. Collectively, the current data identifies EMD1214063 as a potent MET small-molecule inhibitor with selective activity towards mutated MET variants. Mol Cancer Ther; 12(11); 2415–24. ©2013 AACR.